Stockreport

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Opiant Pharmaceuticals, Inc.  (OPNT) 
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
PDF SANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademar [Read more]